broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K59369769-001-22-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.641516 | 8.888537 | 0.410583 | 0.820297 | 0.077135 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000959 |
BRD-K60866521-001-07-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.842594 | -1.295894 | 0.205252 | 0.92628 | 0.057376 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000959 |
BRD-K60997853-001-02-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | -0.143058 | 0.435698 | 0.687461 | 0.700597 | 1.781606 | 0.999987 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000959 |
BRD-K61192372-001-08-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.751571 | -1.679396 | 0.272114 | 0.791137 | 2.232529 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000959 |
BRD-K62008436-001-23-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.099545 | 1.258164 | 0.62139 | 0.744917 | 0.041005 | 0.048918 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000959 |
BRD-K62196610-001-01-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.219218 | 1.135604 | 0.872619 | 0.763799 | 0.547891 | 0.910676 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000959 |
BRD-K62200014-003-10-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.759391 | -0.032156 | -0.043396 | 0.841163 | 75,355,582.34337 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000959 |
BRD-K62391742-001-09-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.821983 | 0.082659 | -0.04723 | 0.909114 | 0.046552 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000959 |
BRD-K62627508-001-01-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.260985 | 1.350441 | 0.86936 | 0.703067 | 0.203286 | 0.351132 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000959 |
BRD-K63504947-001-14-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.178299 | 0.111588 | 0.004781 | 1 | 0.00135 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000959 |
BRD-K63712959-001-01-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.928857 | -0.295912 | -0.056832 | 0.972083 | 0.014002 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000959 |
BRD-K64052750-001-22-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.790274 | 2.971842 | 0.502282 | 0.885007 | 0.048875 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000959 |
BRD-K64881305-001-03-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.15304 | 1.511502 | 0.817065 | 0.414757 | 0.012151 | 0.015474 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000959 |
BRD-K66175015-001-12-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | -0.163528 | 0.502221 | 0.700103 | 0.672165 | 1.092803 | 0.622083 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000959 |
BRD-K67844266-003-01-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.168805 | 1.937285 | 0.787134 | 0.752737 | 0.558549 | 0.690874 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000959 |
BRD-K69001009-001-02-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.847204 | 0.294423 | -0.140963 | 0.940986 | 0.485517 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000959 |
BRD-K69694239-001-02-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.19694 | 3.923739 | 0.856485 | 0.753618 | 0.509239 | 0.578548 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000959 |
BRD-K69776681-001-03-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.177431 | 0.611575 | 0.768348 | 0.383047 | 0.004619 | 0.009457 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000959 |
BRD-K70301465-001-05-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.78225 | 2.85018 | 0.616394 | 0.869023 | 0.029165 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000959 |
BRD-K70401845-001-15-7 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.373676 | 0.922655 | 0.650991 | 0.795231 | 0.443435 | 1.969668 | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000959 |
BRD-K73838513-003-05-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.104226 | 3.754218 | 0.721887 | 0.906385 | 3.648639 | 3.883032 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000959 |
BRD-K74514084-003-09-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.41481 | 1.054982 | 0.45995 | 0.890211 | 1.880959 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000959 |
BRD-K75009076-001-02-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.043296 | 2.090773 | 0.629492 | 0.864188 | 2.592308 | 2.707077 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000959 |
BRD-K76210423-001-01-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.89268 | 8.080523 | 0.483639 | 0.915828 | 0.004948 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000959 |
BRD-K76239644-001-02-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.510825 | 0.93266 | -0.019067 | 0.764619 | 0.09413 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000959 |
BRD-K76674262-001-03-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | -0.070548 | 0.34507 | 0.48958 | 0.583564 | 0.385097 | 0.262695 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000959 |
BRD-K76908866-001-07-6 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.722563 | 6.056696 | 0.324488 | 0.900888 | 0.312132 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000959 |
BRD-K78431006-001-15-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.382016 | 2.356486 | 0.722211 | 0.883865 | 1.62359 | 2.996487 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000959 |
BRD-K79254416-001-21-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.474835 | 0.260839 | 0.518519 | 0.754681 | 0.138157 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000959 |
BRD-K81016934-001-02-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.948382 | -0.309545 | -0.039018 | 0.973992 | 0.082839 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000959 |
BRD-K81418486-001-44-2 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.654713 | 0.345861 | 0.056031 | 0.81094 | 0.039771 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000959 |
BRD-K81473043-001-19-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.270124 | 2.473561 | 0.648224 | 0.954325 | 0.376985 | 0.516135 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000959 |
BRD-K82135108-001-04-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.890841 | 0.036994 | 0.006198 | 0.938972 | 0.000125 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000959 |
BRD-K82746043-001-19-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.297821 | 7.937336 | 0.428871 | 0.849409 | 1.247701 | 1.398498 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000959 |
BRD-K82818427-001-04-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.689594 | -1.193191 | 0.055261 | 0.975236 | 0.000866 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000959 |
BRD-K83029223-001-01-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.186497 | 1.854261 | 0.912114 | 0.62922 | 0.007496 | 0.009642 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000959 |
BRD-K83988098-001-02-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.883893 | -0.249494 | 0.006186 | 0.987613 | 0 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000959 |
BRD-K85402309-043-01-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.319245 | 3.66707 | 0.720535 | 0.795615 | 0.542772 | 0.716339 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000959 |
BRD-K85606544-001-09-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.292188 | 0.995881 | 0.690428 | 0.773985 | 0.472036 | 1.139859 | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000959 |
BRD-K86118762-001-01-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.103945 | 0.874871 | 0.047644 | 1 | 0.016292 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000959 |
BRD-K86972824-001-01-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.888744 | -0.18428 | 0.002381 | 0.968232 | 0.000397 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000959 |
BRD-K87737963-001-06-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.591354 | 2.63165 | 0.505466 | 0.971309 | 5.421642 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000959 |
BRD-K87782578-001-01-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.175218 | 1.891733 | 0.9348 | 0.92745 | 4.78834 | 6.015001 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000959 |
BRD-K87909389-003-03-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.11611 | 1.583192 | 0.9273 | 0.607167 | 0.133995 | 0.158337 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000959 |
BRD-K88510285-001-17-8 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.099508 | 11.954627 | 0.844967 | 0.493437 | 0.010661 | 0.010861 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000959 |
BRD-K89014967-001-04-3 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.717597 | 0.340826 | 0.275098 | 0.848309 | 0.04589 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000959 |
BRD-K92723993-001-17-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.015144 | -0.036219 | -0.001172 | 1 | 801,678,937.356261 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000959 |
BRD-K95142244-001-01-5 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.430701 | 0.647251 | 0.594253 | 0.730851 | 0.104197 | 2.207168 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000959 |
BRD-K98572433-001-02-9 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.224025 | 0.494325 | 0.492962 | 0.780418 | 1.096609 | 3.649024 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000959 |
BRD-K99113996-001-02-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.347532 | 3.844484 | 0.944789 | 0.8791 | 1.656328 | 2.255889 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000959 |
BRD-K99616396-001-05-1 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 0.801908 | -0.262583 | 0.086303 | 0.902624 | 0.06754 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000959 |
BRD-K99749624-001-07-0 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.007262 | 0.095407 | -0.033345 | 1 | 0.149923 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000959 |
BRD-M97302542-001-04-4 | ACH-000959 | SNUC4_LARGE_INTESTINE | MTS010 | 1 | 1.057335 | 0.00609 | -0.003361 | 1 | 0.549841 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000959 |
BRD-A25234499-001-19-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.821911 | 1.424894 | 0.269591 | 0.917254 | 0.110161 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000961 |
BRD-A70858459-001-01-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | -0.074628 | 2.931217 | 0.323684 | 0.984783 | 12.702431 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000961 |
BRD-A74914197-001-02-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.42053 | 0.044805 | 0.017642 | 1 | 0.002228 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000961 |
BRD-K02113016-001-19-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.902206 | -2.469596 | -0.08131 | 0.940896 | 0.215066 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000961 |
BRD-K02130563-001-11-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.091423 | 1.034066 | 0.865867 | 0.424747 | 0.020968 | 0.02549 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000961 |
BRD-K03390685-001-01-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.54723 | 5.641123 | 0.543547 | 1 | 1.362576 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000961 |
BRD-K03406345-001-21-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.853059 | -1.898497 | 0.054923 | 0.956589 | 0.010703 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000961 |
BRD-K03449891-001-08-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.912331 | 0.103914 | -0.017491 | 0.944947 | 0.000235 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000961 |
BRD-K03765900-001-01-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.215927 | 0.16665 | 0.188427 | 0.665748 | 0.510445 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000961 |
BRD-K05804044-001-18-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.418308 | 0.641934 | 0.152156 | 1 | 24.969452 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000961 |
BRD-K06814349-304-02-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.180491 | 0.788542 | 0.716203 | 0.740407 | 0.516473 | 0.911356 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000961 |
BRD-K08109215-001-06-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.681639 | 7.122958 | 0.477782 | 0.965774 | 3.523107 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000961 |
BRD-K08542803-001-02-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | -0.052046 | 0.647952 | 0.757843 | 0.615731 | 0.33045 | 0.283625 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000961 |
BRD-K08547377-001-04-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.110937 | 0.660688 | -0.040537 | 1 | 0.056585 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000961 |
BRD-K08703257-001-13-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.059907 | -2.213376 | -0.010598 | 1 | 0.015836 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000961 |
BRD-K08799216-001-05-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.404888 | 0.722815 | 0.590845 | 0.775511 | 0.27969 | 2.778438 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000961 |
BRD-K09951645-001-11-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.587927 | 0.112996 | 0.048243 | 0.780387 | 0.023593 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000961 |
BRD-K11267252-001-05-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.858799 | 0.619748 | 0.051435 | 0.95914 | 0.80486 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000961 |
BRD-K11630072-001-13-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.935816 | -0.03654 | -0.014558 | 0.967988 | 0.068108 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000961 |
BRD-K12184916-001-19-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.494347 | 0.694293 | 0.21789 | 0.585791 | 0.002085 | 1.327458 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000961 |
BRD-K12343256-001-14-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.478879 | 0.350004 | 0.08044 | 1 | 0.099328 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000961 |
BRD-K13049116-001-04-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.685272 | 2.301671 | 0.212422 | 0.990263 | 10.018388 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000961 |
BRD-K13390322-001-06-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.153043 | 11.937887 | 0.666078 | 0.81106 | 1.147584 | 1.183278 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000961 |
BRD-K13514097-001-04-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.451928 | -0.068374 | 0.092301 | 0.722787 | 0.109981 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000961 |
BRD-K13662825-001-07-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.07153 | 5.939967 | 0.593722 | 0.700712 | 0.109602 | 0.112489 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000961 |
BRD-K14109347-001-03-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.097941 | 4.217588 | 0.796181 | 0.834324 | 1.682571 | 1.771799 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000961 |
BRD-K15179879-001-03-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.105557 | 1.359245 | 0.655499 | 0.394031 | 0.013807 | 0.016439 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000961 |
BRD-K15600710-066-05-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.269635 | 7.605471 | 0.685422 | 0.778562 | 0.517856 | 0.573401 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000961 |
BRD-K16730910-001-10-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.908827 | -2.810338 | -0.008928 | 0.938367 | 0.431003 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000961 |
BRD-K17610631-001-03-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.193898 | 0.447225 | 0.460877 | 0.760788 | 1.004244 | 3.008449 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000961 |
BRD-K17743125-001-08-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.156985 | 6.399807 | 0.737258 | 0.853383 | 1.849205 | 1.961347 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000961 |
BRD-K17894950-001-14-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.120994 | -0.019513 | -0.110892 | 1 | 0.606713 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000961 |
BRD-K18961567-001-01-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.386802 | 1.029975 | 0.272827 | 0.919715 | 3.809829 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000961 |
BRD-K19540840-001-09-4 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.761718 | 2.663305 | 0.202329 | 0.902894 | 0.191612 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000961 |
BRD-K19687926-001-04-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.954574 | -0.270126 | 0.002446 | 0.968611 | 2.274591 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000961 |
BRD-K19796430-001-05-6 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.067311 | 0.007257 | -0.008073 | 1 | 96,225,883,868,383.5 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000961 |
BRD-K22064724-001-01-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.058619 | 3.018158 | 0.799822 | 0.735867 | 0.656876 | 0.684584 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000961 |
BRD-K22822991-001-02-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.888059 | 0.260936 | 0.054359 | 0.954231 | 0.384734 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000961 |
BRD-K23228615-001-02-8 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.12382 | 0.154195 | -0.060362 | 1 | 0.051077 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000961 |
BRD-K23984367-001-07-5 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.071842 | -0.240484 | -0.037971 | 1 | 2.462162 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000961 |
BRD-K26026438-001-01-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.543156 | 0.681173 | 0.465345 | 0.865344 | 0.707412 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000961 |
BRD-K26657438-001-15-2 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.907622 | 4.511397 | 0.138207 | 0.97209 | 0.532854 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000961 |
BRD-K28822270-001-03-7 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | -0.269291 | 1.365663 | 0.743679 | 0.791203 | 2.230203 | 1.626803 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000961 |
BRD-K29905972-001-06-3 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.777666 | 0.159156 | 0.006928 | 0.946013 | 136.076552 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000961 |
BRD-K30577245-001-05-0 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.175246 | 1.48351 | 0.801094 | 0.611576 | 0.006471 | 0.008656 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000961 |
BRD-K31698212-001-02-9 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 0.661754 | 1.268736 | 0.420848 | 0.906448 | 0.701155 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000961 |
BRD-K31928526-001-02-1 | ACH-000961 | ISHIKAWAHERAKLIO02ER_ENDOMETRIUM | MTS010 | 1 | 1.096515 | -0.078976 | -0.026752 | 1 | 0.914983 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000961 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.